Clinical trials: Phase 2
Amyotrophic Lateral Sclerosis
A 6-Month Extension Study to Assess the Long-Term Safety of Engensis in Amyotrophic Lateral Sclerosis
The purpose of this study is to evaluate the long-term safety of intramuscular administration of Engensis in Participants with Amyotrophic Lateral Sclerosis who were previously randomized, received treatment, and completed the…
- Trial name
- REViVALS-1B (NCT05176093)
- Testing
- Engensis
- Where
- 2 sites in United States, South Korea
- Volunteers
- 8 people
- Sponsor
- Helixmith Co., Ltd.
Adult Brain Tumor
Antineoplaston Therapy in Treating Adult Patients With Anaplastic Astrocytoma
RATIONALE: Current therapies for adults with anaplastic astrocytoma provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of adults with…
- Trial name
- AA (NCT00003537)
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Burzynski Research Institute
Duchenne Muscular Dystrophy
Safety and Dose Finding Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
The main objective of this study is to evaluate the safety of a high (80mg/kg) and low (40mg/kg) dose of NS-065/NCNP-01 delivered as an intravenous infusion in patients with Duchenne Muscular Dystrophy (DMD) amendable to exon 53…
- Trial name
- NCT02740972
- Testing
- NS-065/NCNP-01
- Where
- 7 sites in United States, Canada
- Volunteers
- 16 people
- Sponsor
- NS Pharma, Inc.
Concussion, Traumatic Brain Injury
Advanced MRI Applications for Mild Traumatic Brain Injury-Phase 2
This is an open-label, non-randomized, prospective, multi-site, parallel group (segment), hypothesis-generating study designed to collect data that will aid in future scientific and engineering exploration of correlations between…
- Trial name
- mTBI-phase2 (NCT02556177)
- Testing
- MRI
- Where
- 7 sites in United States
- Volunteers
- 477 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Pancreatic Cancer
Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy
Cancer results from multiple mutations which cause cells to grow uncontrolled. It therefore may be necessary to inhibit several oncogenic targets to affect cancer cell growth.
- Trial name
- NCT01056601
- Testing
- Bortezomib, Panobinostat
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Postherpetic Neuralgia
Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia
Evaluation of the efficacy of LX9211 compared to placebo in reducing pain related to postherpetic neuralgia over an 11 week assessment period.
- Trial name
- RELIEF-PHN1 (NCT04662281)
- Testing
- LX9211
- Where
- 32 sites in United States, Czechia and 1 more
- Volunteers
- 79 people
- Sponsor
- Lexicon Pharmaceuticals
Covid-19
Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients
To evaluate the safety and efficacy of antroquinonol treatment of mild to moderate pneumonia due to COVID-19, as measured by the proportion of patients alive and free of respiratory failure.
- Trial name
- NCT04523181
- Testing
- Antroquinonol
- Where
- 15 sites in United States, Argentina and 1 more
- Volunteers
- 124 people
- Sponsor
- Golden Biotechnology Corporation
Myxofibrosarcoma, Recurrent Adult Soft Tissue Sarcoma
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
This phase II trial studies how well alisertib works in treating patients with sarcoma that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or has spread to other places…
- Conditions
- Myxofibrosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Leiomyosarcoma, Recurrent Liposarcoma
- Trial name
- NCT01653028
- Testing
- Alisertib, Laboratory Biomarker Analysis
- Where
- 235 sites in United States
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Generalized Pustular Psoriasis
Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis
To evaluate efficacy, safety, and tolerability of spesolimab (BI 655130) compared to placebo in patients with Generalized Pustular Psoriasis (GPP) presenting with an acute flare of moderate to severe intensity.
- Trial name
- NCT03782792
- Testing
- Spesolimab
- Where
- 37 sites in United States, China and 10 more
- Volunteers
- 53 people
- Sponsor
- Boehringer Ingelheim
Advanced Solid Tumours
The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.
This is a 2 parts phase I, open label trial of olaparib monotherapy and olaparib in combination with paclitaxel in patients with solid tumours.
- Trial name
- NCT02430311
- Testing
- Olaparib, Paclitaxel
- Where
- 3 sites in China
- Volunteers
- 36 people
- Sponsor
- AstraZeneca
Postsurgical Pain
Study of CA-008 (Vocacapsaicin) in Total Knee Arthroplasty
This is a two-part, Phase 2, multi-center, randomized, double-blind, placebo-controlled, parallel design study of CA-008 (vocacapsaicin) vs. placebo injected/instilled during an elective TKA.
- Trial name
- NCT03731364
- Testing
- CA-008
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Concentric Analgesics
Lung Cancer
Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer.
This study will evaluate the efficacy and safety of chemotherapy given prior to having lung cancer surgically removed. Patients with resectable non-small cell lung cancer will receive gemcitabine and pemetrexed together for 4…
- Trial name
- NCT00226577
- Testing
- Gemcitabine, Pemetrexed, Surgery
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Advanced Non-clear Cell Renal Cell Carcinoma
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
To compare the anti-tumor activity of everolimus and sunitinib in subjects with metastatic renal cell carcinoma (mRCC) with non-clear cell pathology.
- Trial name
- ASPEN (NCT01108445)
- Testing
- Everolimus, Sunitinib
- Where
- 18 sites in United States, Canada and 1 more
- Volunteers
- 131 people
- Sponsor
- Duke University
Unresectable Pancreatic Cancer
MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer
This research study is for people who have pancreas cancer for which surgery is not recommended. Potential patients must have already received several months of chemotherapy before they are eligible for this study and there will…
- Trial name
- NCT01972919
- Testing
- Radiation Therapy, Concurrent chemotherapy (Gemcitabine, Capecitabine)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Medical College of Wisconsin
Carcinoma, Renal Cell
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
Phase II, multi-center, two-stage study utilising a randomised discontinuation design to evaluate the safety and efficacy of GW786034 (pazopanib) in adult subjects with locally recurrent or metastatic clear-cell Renal Cell…
- Trial name
- NCT00244764
- Testing
- GW786034
- Where
- 45 sites in United States, Australia and 6 more
- Volunteers
- 225 people
- Sponsor
- GlaxoSmithKline
Migraine Disorders
A Multicenter Assessment of ALD403 in Chronic Migraine
The purpose of this study is to assess ALD403 in the prevention of migraine headache in chronic migraineurs.
- Trial name
- NCT02275117
- Testing
- ALD403
- Where
- 92 sites in United States, Australia and 2 more
- Volunteers
- 665 people
- Sponsor
- Alder Biopharmaceuticals, Inc.
Salivary Gland Cancer
Amivantamab in Adenoid Cystic Carcinoma
The purpose of the study is to determine if treatment with amivantamab will be efficacious in patients with recurrent and metastatic adenoid cystic carcinoma.
- Trial name
- NCT05074940
- Testing
- Amivantamab
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- Trisha Wise-Draper
Glaucoma, Open-Angle, Ocular Hypertension
A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329
This study will characterize the effect of PF-04217329, alone and in combination with latanoprost, on circadian intraocular pressure and blood pressure in glaucoma patients.
- Trial name
- NCT00934089
- Testing
- PF-04217329, latanoprost vehicle, latanoprost
- Where
- 8 sites in United States
- Volunteers
- 31 people
- Sponsor
- Pfizer
Hepatitis B, Chronic
A Study in Healthy Volunteers and in Participants With Chronic Hepatitis B to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7020531
This sponsor-open, investigator- and participant-blinded, multi-center study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7020531 in healthy participants and in participants with chronic…
- Trial name
- NCT02956850
- Testing
- RO7020531
- Where
- 18 sites in Bulgaria, Hong Kong and 6 more
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Esophagus Cancer, Esophageal Cancer
Proton Beam Therapy in the Treatment of Esophageal Cancer
The investigators plan to include both operable and inoperable patients with esophagus cancer in this prospective trial. Since both proton and photon treatments are biologically equivalent, the investigators do not expect a…
- Conditions
- Esophagus Cancer, Esophageal Cancer, Cancer of the Esophagus
- Trial name
- NCT03482791
- Testing
- Proton beam therapy, Patient-Reported Outcome Measures
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Washington University School of Medicine